NCT02769520View on ClinicalTrials.gov

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 6, 2016

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Pembrolizumab

200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression

Trial Locations (3)

90505

University of California Los Angeles, Torrance

92093

UCSD Moores Cancer Center, La Jolla

94115

University of California San Francisco, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Assuntina G. Sacco, MD

OTHER